Latest From ApolloBio Corp.
ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.
In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Neurology, Nervous System
- Company Type
- Parent & Subsidiaries
- ApolloBio Corp.
- Senior Management
Weipang Yang, PhD, CEO
Yanqiu Zhang, CFO
Dawei Jiang, Dir., Bus. Dev. & Licensing
- Contact Info
Phone: 10 85711134
Seasons House, Jung Wang Fu, No. 19
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.